Siblings Periodical Articles [33/33] Collection Statistics Item counts issued in 3 years:4(44.44%) Items With Fulltext:9(100.00%) Download counts of the item Download times greater than 0:9(100.00%) Download times greater than 100:6(66.67%) Total Bitstream Download Counts:1118(14.07%) Last Update: 2025-04-17 12:36 Top Upload Loading... Top Download Loading... Recent Submissions TCOG T5221 trial: A phase II random... Single-cell RNA sequencing via Endo... Nivolumab plus ipilimumab (N plus I... Aristolochic acid (AA) exposure and... Outcomes of post-immunotherapy dura... A phase II trial of nivolumab, gemc... Potential roles of gut microbiome i... Improved survival with neoadjuvant ... A phase II trial of nivolumab and g...

Jump to a point in the index: (Choose year) 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 1-9 of 9. (1 Page(s) Totally) 1  View [10|25|50] records per page

Date	Title	Relation
2024-09	TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S-1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer	Annals of Oncology. 2024 Sep;35(Suppl. 2):S932-S933.
2023-11	Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome	Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390.
2023-11	Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis	Annals of Oncology. 2023 Nov;34(Suppl. 4):S1536-S1537.
2023-06	Aristolochic acid (AA) exposure and telomere maintenance mechanism in liver angiosarcoma (AS)	Journal of Clinical Oncology. 2023 Jun;41(16 Suppl.):Meeting Abstract 11551.
2022-10	Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression	Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412.
2022-07	Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors	Annals of Oncology. 2022 Jul;33(Suppl. 6):S484.
2022-07	Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience	Annals of Oncology. 2022 Jul;33(Suppl. 6):S535.
2022-07	A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer	Annals of Oncology. 2022 Jul;33(Suppl. 6):S478.
2021-09	A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer	Annals of Oncology. 2021 Sep;32(Suppl. 5):S377.

Showing items 1-9 of 9. (1 Page(s) Totally) 1  View [10|25|50] records per page